15
BioTech Sage Report, May 2001
Institutional
Ownership
Institutional
Ownership +/-
Comments
72%
-3%
Q1-01 EPS a loss of 9˘ vs. a loss of Q1-00 6˘ EPS. ABGX will continue to form collaborations, buy below $40.
59%
-3%
Q1 EPS 6˘ lowered than expected. AFFX`s 2001 EPS of 21˘. Maintain buy at this price level.
60%
+2%
Q1 EPS. On track with fall 2001 launch of Flumist provided with FDA approved. Buy under $40.
72%
+3%
The NDA for Attenade (ADHD ) is expected to have FDA completed review by Q3-01. Buy below $25.
49%
+2%
CEGE is a long term play.
20%
NC
CIPH to report Q1-01 earnings on May 1.
77%
NC
CORR still on track to be profitable this year, rate as a buy.
22%
-1%
Provenge for prostate cancer on track for 2002 launch. Attractive buy below $10.
12%
+1%
Report 1st qtr earnings on 4-19, GZBX continues to restructure and wait to see improve profitability.
33%
NC
Q1 EPS of a loss of 12˘ vs. 14˘ Q1-00. Long term play.
37%
-1%
Cialis NDA filing in 2001, expected FDA approval 2002. Buy below $50.
55%
+27%
FDA filing mid-2001 for its C225. Reported 4th qtr earnings. Buy on the dips.
78%
NC
BLA filing for inhaled insulin at the end of the year. Rate as buy.
56%
+1%
Abraelix remains on track for submission of FDA approval, buy on the dips.
82%
-4%
Q1-01 EPS loss of 63˘ vs Q1-00 EPS of 76˘. Consensus loss of 98˘. Buy on strength of EPS and revenue.
29%
+2%
NDA filing for pancreatic cancer second half of 2001. SUPG share price has stabilized, buy below $10.
61%
-1%
Lead AIDS drug on track and projected to be launched in 2002, profitable by 2003, buy on the dips.
80%
-1%
Filing of NDA for tenofovir for AIDS by mid-year. Buy on the dips.
58%
-3%
CAMPATH waiting for final FDA approval.
80%
-1%
Buy on the dips.
70%
NC
VRTX to buy ABSC. Continued to make progress on its product pipeline. Buy on the dips.
56%
NC
Aranesp near term approval and continued growth with product pipeline. Still rate as a buy.
49%
NC
1st qtr earnings in line with the Street. BGEN reaffirms 2001 guidance. Still rate as a buy.
31%
-1%
Q1 EPS 19˘. Beat estimates by 2˘ Expected growth will be sure and steady. Buy on dips.
78%
-6%
Q1 quarter of EPS 55
˘
compared to 53
˘
. 2001 Renagel will support growth of 2001 EPS forecast of $2.25 to $2.35. 2: 1 split in 5-01
37%
+1%
FDA hearing on Xolair delayed, Velentri studies to re-envaluated.. Rate as hold.
81%
-2%
2001 Q1 EPS of 12˘ compared to 2000 Q1 of a loss of 3˘. Delayed Zevalin FDA approval. Buy on dips.
40%
-1%
2001 Q1 EPS of 7˘ compared to 2001 Q1 of 6˘.
70%
NC
Continued strong sales and product pipeline. Buy on the dips.
81%
+1%
Stock to split 2:1 in 5-01 and the company outlook remains upbeat. Buy on the dips.
Tools Institutional Ownership, somebody knows something ....
What's the big money doing? Institutional ownership tracks investment by mutual funds, pension plans, banks, insurance companies, and stock brokerages.
Institutional ownership is a handy benchmark of conventional wisdom on Wall Street. Beyond that, things get tricky.
